STGD1 clinical trials at UCSF
1 research study open to eligible people
Stargardt disease (STGD1) is an inherited retinal disease that reduces the ability to see fine detail. UCSF is evaluating tinlarebant to study its safety and effects on vision in STGD1. UCSF is performing eye tests and scans and tracking any side effects over time.
Showing trials for
Tinlarebant in Subjects With Stargardt Disease
open to eligible people ages 12-20
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
San Francisco, California and other locations
Last updated: